Analysis of multipotent mesenchymal stromal cells used for acute graft‐versus‐host disease prophylaxis. (20th July 2015)

• Record Type: Journal Article
• Authors: Kuzmina, Larisa A.; Petinati, Nataliya A.; Shipounova, Irina N.; Sats, Natalia V.; Bigildeev, Alexey E.; Zezina, Ekaterina A.; Popova, Maria D.; Drize, Nina J.; Parovichnikova, Elena N.; Savchenko, Valery G.
• Is Part Of: European journal of haematology. Volume 96:Number 4(2016:Apr.)
• Page Start: 425
• Page End: 434
• Publication Date: 2015-07-20
• Subjects: acute graft‐versus‐host disease prophylaxis -- mesenchymal stromal cell -- colony‐forming unit fibroblast -- gene expression; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12613
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Background: Multipotent mesenchymal stromal cells (MSCs) are used for prophylaxis of acute graft‐versus‐host disease (aGvHD) after allogeneic hematopoietic cell transplantation (allo‐HCT). Not all samples of MSC are efficient for aGvHD prevention. The suitability of MSCs for aGvHD prophylaxis was studied. Methods: MSCs were derived from the bone marrow (BM) of HCT donor and cultivated for no more than three passages. The characteristics of donor BM samples including colony‐forming unit fibroblast (CFU‐F) concentration, growth parameters of MSCs, and the relative expression levels (REL) of different genes were analyzed. MSCs were injected intravenously precisely at the moment of blood cell reconstitution. Results: MSCs infusion induced a significant threefold decrease in aGvHD development and improved overall survival compared with the standard prophylaxis group. In ineffective MSC samples (9.4%), a significant decrease in total cell production and the REL of CSF1, FGFR1, and PDGFRB was observed. In all studied BM samples, the cumulative MSC production and CFU‐F concentrations decreased with age. The expression levels of FGFR2, PPARG, and VEGF differed by age. Conclusions: A universal single indicator for the prediction of MSC eligibility for aGvHD prophylaxis was not identified. A multiparameter mathematical model for selecting MSC samples effective for the prevention of aGvHD was proposed.